David M. Hyman

David M. Hyman, MD is Chief Medical Officer for Oncology at AstraZeneca, having previously served as Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. He is one of the world's foremost experts on tissue-agnostic oncology drug development and has played a central role in the clinical programs that led to the first two tissue-agnostic FDA approvals: larotrectinib and entrectinib for NTRK fusion-positive solid tumors. Hyman led LOXO-101 (larotrectinib) early-phase trials at MSKCC, demonstrating unprecedented response rates of approximately 75% across 17 tumor histologies harboring NTRK gene fusions, irrespective of tumor type. His work fundamentally redefined the regulatory paradigm for oncology drug approval, shifting the focus from histology-based indications to molecularly defined biomarker populations. He has also contributed to the clinical development of drugs targeting FGFR alterations and has published over 250 peer-reviewed articles on genomic biomarkers and targeted therapy.